FDA Inspection 1075566 — Morteza Nadjafi, M.D.
The FDA completed an inspection of Morteza Nadjafi, M.D. on Dec 13, 2018 in Orlando, FL. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Dec 13, 2018
- Fiscal Year
- 2019
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Orlando, FL (United States)
Additional Details
Clinical Investigator (CI)